Behavioral indices in antipsychotic drug discovery

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 3, 2010, Pages 632-638

  Porsolt, Roger D ^a   Moser, Paul C ^a   Castagné, Vincent ^a  

^a Porsolt and Partners Pharmacology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; AMPHETAMINE; APOMORPHINE; ARIPIPRAZOLE; ATROPINE; CHLORPROMAZINE; CLOZAPINE; DIZOCILPINE; DOPAMINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; KETAMINE; MESCALINE; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SCOPOLAMINE; SEROTONIN; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG; VOLINANSERIN; ZIPRASIDONE;

AGITATION; AKATHISIA; ANHEDONIA; ANTIPSYCHOTIC ACTIVITY; ATTENTION; AVOIDANCE BEHAVIOR; BLOOD DYSCRASIA; BLOOD PRESSURE REGULATION; CATALEPSY; COGNITIVE DEFECT; DEFECATION; DELUSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; HYPERACTIVITY; LEARNING; MEMORY; MONKEY; MOOD DISORDER; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; PARANOIA; PARKINSONISM; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL INTERACTION; STEREOTYPY; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR; BEHAVIOR, ANIMAL; COGNITION DISORDERS; DRUG DISCOVERY; DYSKINESIA, DRUG-INDUCED; HUMANS; PSYCHOTIC DISORDERS;

EID: 77952331747     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166710     Document Type: Review

References (45)

1. Auclair AL, Kleven MS, Besnard J, Depoortère R, and Newman-Tancredi A (2006) Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 31:1900-1909. (Pubitemid 44246336)
2. Bast T, Zhang W, Feldon J, and White IM (2000) Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem Behav 67:647-658. (Pubitemid 32103577)
3. Becker A and Grecksch G (2004) Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry 28:1267-1277.
4. Boulay D, Depoortère R, Louis C, Perrault G, Griebel G, and Soubrié P (2004) SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46:1121-1129. (Pubitemid 38529936)
5. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186.
6. Casey DE (1993) Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am 16:589-610.
7. Castagné V, Moser PC, and Porsolt RD (2009) Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol 57:381-418.
8. Clow A, Jenner P, Theodorou A, and Marsden CD (1979) Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months. Nature 278:59-61. (Pubitemid 9105109)
9. Cook L, Tam SW, and Rohrbach KW (1992) DuP 734 [1-(cyclopropylmethyl)-4- (2′(4″-fluorophenyl)-2′- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects. J Pharmacol Exp Ther 263:1159-1166. (Pubitemid 23157194)
10. Cook L and Weidley E (1957) Behavioral effects of some psychopharmacological agents. Ann N Y Acad Sci 66:740-752.
11. Corbett R, Zhou L, Sorensen SM, and Mondadori C (1999) Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology 21:S211-S218.
12. Costall B, Domeney AM, and Naylor RJ (1982) Behavioural and biochemical consequences of persistent overstimulation of mesolimbic dopamine systems in the rat. Neuropharmacology 21:327-335. (Pubitemid 12158500)
13. Coyle JT, Tsai G, and Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 1003:318-327. (Pubitemid 38083065)
14. Deniker P, Ginestet D, and Loo H (1980) Maniement des Médicaments Psychotropes, Doin Editeurs, Paris.
15. Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, et al. (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30:1963-1985. (Pubitemid 43093498)
16. Didriksen M, Skarsfeldt T, and Arnt J (2007) Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 193:225-233. (Pubitemid 47025022)
17. Gabrovska VS, Laws KR, Sinclair J, and McKenna PJ (2003) Visual object processing in schizophrenia: evidence for an associative agnosic deficit. Schizophr Res 59:277-286. (Pubitemid 35284702)
18. Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, et al. (2007) ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther 322:862-870. (Pubitemid 47105818)
19. Geyer MA and Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1071-1079.
20. Grayson B, Idris NF, and Neill JC (2007) Atypical antipsychotics attenuate a subchronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184:31-38. (Pubitemid 47404650)
21. Gunne LM and Barany S (1976) Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology (Berl) 50:237-240.
22. Heise GA and Boff E (1962) Continuous avoidance as a base-line for measuring behavioral effects of drugs. Psychopharmacologia 3:264-282.
23. Jones DNC, Gartlon JE, Minassian A, Perry W and Geyer M (2008) Developing new drugs for schizophrenia: from animals to the clinic. Animal and Translational Models for CNS Drug Discovery Volume1: Psychiatric Disorders. (McArthur RA and Borsini F eds), pp 199-261, Elsevier, New York.
24. Leite JV, Guimarães FS, and Moreira FA (2008) Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 578:222-227.
25. Markou A, Chiamulera C, Geyer MA, Tricklebank M, and Steckler T (2009) Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34:74-89.
26. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, et al. (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[ 6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486-496.
27. Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, and Lowe DA (2003) Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl) 165:128-135. (Pubitemid 36056989)
28. Martinez ZA, Halim ND, Oostwegel JL, Geyer MA, and Swerdlow NR (2000) Ontogeny of phencyclidine and apomorphine-induced startle gating deficits in rats. Pharmacol Biochem Behav 65:449-457.
29. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 99 (Suppl):S18-S27.
30. Morgan CJ and Curran HV (2006) Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl) 188:408-424. (Pubitemid 46758974)
31. Muscat R and Willner P (1989) Effects of dopamine receptor antagonists on sucrose consumption and preference. Psychopharmacology (Berl) 99:98-102. (Pubitemid 19201723)
32. Nagai T, Noda Y, Une T, Furukawa K, Furukawa H, Kan QM, and Nabeshima T (2003) Effect of AD-5423 on animal models of schizophrenia: phencyclidine- induced behavioral changes in mice. Neuroreport 14:269-272. (Pubitemid 36308425)
33. O'Neill MF and Shaw G (1999) Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl) 145:237-250.
34. Orsetti M, Canonico PL, Dellarole A, Colella L, Di Brisco F, and Ghi P (2007) Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology 32:1783-1790. (Pubitemid 47076374)
35. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34. (Pubitemid 44967781)
36. Porsolt RD, Le Pichon M, and Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732. (Pubitemid 8073804)
37. Pouzet B, Didriksen M, and Arnt J (2002) Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol Biochem Behav 71:635-643. (Pubitemid 34219214)
38. Sachdev PS and Brüne M (2000) Animal models of acute drug-induced akathisia - a review. Neurosci Biobehav Rev 24:269-277. (Pubitemid 30227247)
39. Sams-Dodd F (1999) Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 10:59-90.
40. Snigdha S and Neill JC (2008) Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats-a preliminary investigation. Behav Brain Res 187:489-494.
41. Stewart BR, Rupniak NM, Jenner P, and Marsden CD (1988) Animal models of neuroleptic-induced acute dystonia. Adv Neurol 50:343-359.
42. Suemaru K, Yasuda K, Umeda K, Araki H, Shibata K, Choshi T, Hibino S, and Gomita Y (2004) Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinic alpha7 receptors. Br J Pharmacol 142:843-850. (Pubitemid 38998098)
43. Sun T, Hu G, and Li M (2009) Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 602:334-342.
44. Wadenberg ML and Hicks PB (1999) The conditioned avoidance response test reevaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862.
45. Willner P (1991) Methods for assessing the validity of animal models of human psychopathology, in Animal Models in Psychiatry (Boulton A, Baker G, and Martin-Iverson M eds) pp 1-23, Humana Press, Clifton, NJ.